McArtney Rowena, Atkinson Angharad
Cardiff and Vale UHB.
Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.39.
Local Guidelines for peri-operative pain management in children published in 2012 recommended that paracetamol dosing was calculated using ideal body weight (IBW) to prevent inadvertent overdosing in overweight and obese children.1 The purpose of this audit was to establish compliance with these guidelines. The oral paracetamol dose recommended was 20-30 mg/kg as a single dose then 15-20 mg/kg every 4-6 hrs with a maximum of 90 mg/kg/day. IV paracetamol doses were as recommended in BNF for Children (BNFC).2 BNFC states that paracetamol doses totalling 150 mg/kg may cause severe hepatocellular necrosis and renal tubular necrosis but the potential for adverse effects in some children can be seen with doses as little as 75 mg/kg in 24 hrs.
Paediatric Surgical patients prescribed paracetamol as an inpatient or on discharge over a 10 week period were included in the audit. For this audit patients were assessed as overweight or obese using age and gender specific UK growth charts endorsed by the Department of Health.
100% compliance with the following:1. inpatient charts and discharge prescriptions document patient weight and height.2. paracetamol prescriptions based on ideal weight for height in overweight and obese paediatric patients.3. prescriptions have IV route prescribed independently to oral (PO) or rectal route.4. patients prescribed IV paracetamol reviewed after 48 hrs for an oral switch.
100 inpatient prescriptions (71 elective and 29 non-elective) and 35 discharge prescriptions were analysed.1. Weight was annotated for 84% of inpatient prescriptions and 94% of discharge prescriptions; height was not documented for any patient. Therefore data was analysed basing IBW on 50th centile of the UK growth charts.2. The following results are based on IBW: ▸ Six inpatients prescribed oral paracetamol were classified as overweight or obese; doses ranged from 17.4-30 mg/kg/dose. ▸ Four patients prescribed IV paracetamol were classified as overweight or obese; doses ranged from 20-23 mg/kg/dose. ▸ Four patients prescribed the combined route of PO/IV paracetamol were classified as overweight or obese; doses ranged from 18-24 mg/kg/dose. ▸ Six patients prescribed oral paracetamol on discharge were classified as overweight or obese; doses ranged from 13-33 mg/kg/dose.3. Paracetamol was prescribed as IV/PO in 32 inpatients.4. IV paracetamol was prescribed in 52 patients; 20 were not reviewed at 48 hrs for a switch to oral route. Of these, only 3 were appropriate prolonged IV prescriptions.Conclusion Audit findings showed inadequate compliance with local prescribing guidelines posing a risk of inappropriately high doses of paracetamol being prescribed to overweight and obese children. In addition, unnecessarily prolonged IV use was observed. Following feedback local guidelines were amended in 2015 to recommend that in obese children, dosing should reflect lean body mass and ideal weight for height. The maximum daily dose was also reduced to 75 mg/kg/day. Prescribers require education regarding this important issue.
2012年发布的儿童围手术期疼痛管理地方指南建议,对乙酰氨基酚的剂量应根据理想体重(IBW)计算,以防止超重和肥胖儿童意外过量用药。1 本次审核的目的是确定是否符合这些指南。推荐的口服对乙酰氨基酚单剂量为20 - 30毫克/千克,然后每4 - 6小时15 - 20毫克/千克,最大剂量为90毫克/千克/天。静脉注射对乙酰氨基酚的剂量按照《儿童BNF》(BNFC)中的推荐。2 BNFC指出,对乙酰氨基酚总剂量达150毫克/千克可能会导致严重的肝细胞坏死和肾小管坏死,但在某些儿童中,24小时内剂量低至75毫克/千克时就可能出现不良反应。
本次审核纳入了在10周内住院或出院时开具对乙酰氨基酚的儿科手术患者。对于本次审核,使用英国卫生部认可的按年龄和性别划分的生长图表将患者评估为超重或肥胖。
100%符合以下标准:1. 住院病历和出院处方记录患者体重和身高。2. 超重和肥胖儿科患者的对乙酰氨基酚处方基于身高对应的理想体重。3. 处方中静脉注射途径与口服(PO)或直肠途径独立开具。4. 静脉注射对乙酰氨基酚的患者在48小时后接受复查以转为口服给药。
分析了100份住院处方(71份择期和29份非择期)和35份出院处方。1. 84%的住院处方和94%的出院处方标注了体重;没有任何患者记录身高。因此,基于英国生长图表第50百分位数的理想体重来分析数据。2. 以下结果基于理想体重: ▸ 6名开具口服对乙酰氨基酚的住院患者被归类为超重或肥胖;剂量范围为17.4 - 30毫克/千克/剂量。 ▸ 4名开具静脉注射对乙酰氨基酚的患者被归类为超重或肥胖;剂量范围为20 - 23毫克/千克/剂量。 ▸ 4名开具口服/静脉联合途径对乙酰氨基酚的患者被归类为超重或肥胖;剂量范围为18 - 24毫克/千克/剂量。 ▸ 6名出院时开具口服对乙酰氨基酚的患者被归类为超重或肥胖;剂量范围为13 - 33毫克/千克/剂量。3. 32名住院患者的对乙酰氨基酚处方开具为静脉注射/口服。4. 52名患者开具了静脉注射对乙酰氨基酚;20名患者在48小时后未接受转为口服途径的复查。其中,只有3份是适当的延长静脉注射处方。结论审核结果显示对地方处方指南的依从性不足,存在给超重和肥胖儿童开具剂量过高的对乙酰氨基酚的风险。此外,观察到不必要的静脉注射使用时间延长。反馈后,2015年修订了地方指南,建议在肥胖儿童中,剂量应反映瘦体重和身高对应的理想体重。最大日剂量也降至75毫克/千克/天。处方者需要接受关于这个重要问题的教育。